TransMedics Group, Inc. Common Stock (TMDX) Stock Price
TMDXStock
$70.78−38.81%52W
Market Cap$2.45B
P/E12.90x
PEG Ratio0.65
Div yield—
Beta2.13
TMDX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-48.72%
Price vs S&P 500 (4W)-17.59%
PEG Ratio0.65
VGM Score53.00
P/E Ratio (Annual)12.90x
TMDX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.48 | $0.44 | -7.44%(-$0.04) | |
| Q1 2026 | $0.61 | $0.30 | -50.92%(-$0.31) | |
| Q4 2025 | $0.37 | $0.53 | +40.95%(+$0.15) | |
| Q3 2025 | $0.36 | $0.66 | +83.33%(+$0.30) | |
| Q2 2025 | $0.43 | $0.92 | +114.79%(+$0.49) |
TMDX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.00
4.00
3.95
3.95
Industry Peers — Electromedical Equipment(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
TMDXTransMedics Group, Inc. Common Stock | C | B | D | 3.7x | 88.2% | 58.7% | 12.2% | $70.78 |
| MDTMedtronic plc | B | C | B | 3.2x | 3.8% | 65.7% | 18.1% | $94.75 |
| ITGRInteger Holdings Corporation | C | C | A | 2.3x | 11.6% | 26.1% | 9.7% | $126.70 |
| LIVNLivaNova PLC Ordinary Shares | C | B | B | 2.9x | 8.2% | 68.1% | 12.5% | $77.58 |
| AXGNAxogen, Inc. Common Stock | F | B | B | 8.1x | 14.9% | 74.6% | -11.8% | $34.62 |
| BLFSBioLife Solutions Inc. | F | C | A | 18.4x | 14.9% | 63.9% | 2.9% | $38.61 |
| CNMDCONMED Corporation | B | C | B | 1.0x | 9.8% | 55.8% | 8.0% | $46.72 |
| CBLLCeriBell, Inc. Common Stock | F | A | A | 9.4x | — | 88.9% | -68.6% | $25.04 |
| INMDInMode Ltd. Ordinary Shares | A | D | C | 2.2x | 12.4% | 76.5% | 18.5% | $14.16 |
| CVCapsoVision, Inc. Common Stock | F | D | B | 25.0x | — | 50.9% | -217.1% | $6.53 |
| ELMDElectromed, Inc. | C | B | C | 3.1x | 15.6% | 78.5% | 18.8% | $27.42 |
About TransMedics Group, Inc. Common Stock
TransMedics Group Inc develops the Organ Care System (OCS), a portable organ perfusion and monitoring platform that preserves donor organs in near-physiologic conditions outside the body. The company's technology addresses significant limitations of traditional cold storage preservation, potentially improving organ quality and transplant outcomes. As a commercial-stage medical technology company, TransMedics is expanding its organ preservation system across multiple transplant disease states.